ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 489.7 | 380.6 | 170.8 |
| Other income | 1.6 | 15.2 | 2.6 |
| Total income | 491.2 | 395.8 | 173.3 |
| Profit before exceptional items & tax | 28.3 | 28.8 | 2.8 |
| Profit before tax | 27.4 | 28.9 | 2.4 |
| Net profit | 18.6 | 21.4 | 1.6 |
| Operating margin | 5.6% | 7.3% | 1.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1062.50% |
|---|---|
| Net profit, quarter on quarter | -13.10% |
| Revenue, year on year | +186.70% |
| Operating profit, year on year | +13250.00% |
| Operating profit, quarter on quarter | +96.30% |
BSE results filing, NSE: MUKKA. Figures extracted from the filing.
Mukka Proteins Ltd: key numbers
- Share price
- ₹26.61
- Market cap
- ₹798.3 Cr
- Revenue (annual)
- ₹1,449 Cr
- Net profit (annual)
- ₹52.06 Cr
- P/E (TTM)
- 10.1×Sector 29.0×
- Promoter holding
- 73.33%+0.00% QoQ
- FII holding
- 1.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mukka Proteins Ltd
All →Mukka Proteins Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹508.9 Cr (+108% YoY), EBITDA ₹50.1 Cr (9.9% margin), PAT ₹17.7 Cr (3.5%). Targets ₹3,000+ Cr revenue by FY30.
Mukka Proteins Results Update
Mukka Proteins reported Q2 FY27 revenue up 108% YoY to Rs.5,088.70 Mn. The Oman facility began commercial production, adding 37,200 MTPA of capacity.
- Oman facility manufacturing capacity
- 37200.0 MTPA
Mukka Proteins Acquisition Worth ₹2.13 Cr
Mukka Proteins' board approved revised terms to acquire 85,200 equity shares, a 46% stake, in Swachha Eco Solutions for up to Rs 2.13 Crore. The unlisted waste-management company is not a related party.
- Value
- ₹2.13 Cr
- Execution
- Up to 31-03-2027
Mukka Proteins Other Announcement
Mukka Proteins filed its quarterly statement of deviation for funds raised through a preferential warrant issue, reporting no deviation. Utilisation of Rs. 11.75 Crore against the working capital object is shown for the quarter ended September 2026.
Mukka Proteins Q2 FY27 Results: Net Profit ₹17.7 Cr, Up 156.5% YoY
Mukka Proteins Ltd reported revenue from operations of ₹508.9 Cr (+108.1% YoY) and net profit of ₹17.7 Cr (+156.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹17.7 Cr · +156.5% YoY
Mukka Proteins Board Meeting Date
Mukka Proteins intimated a board meeting on 07 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closure is also disclosed.